BioAtla (BCAB) Competitors

Compugen (NASDAQ:CGEN) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Do analysts rate CGEN or BCAB?

Compugen currently has a consensus target price of $8.33, indicating a potential upside of 805.90%. BioAtla has a consensus target price of $14.83, indicating a potential upside of 882.34%. Given Compugen's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
BioAtla	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Do insiders and institutionals hold more shares of CGEN or BCAB?

13.3% of Compugen shares are owned by institutional investors. Comparatively, 71.7% of BioAtla shares are owned by institutional investors. 9.5% of Compugen shares are owned by company insiders. Comparatively, 8.4% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is CGEN or BCAB more profitable?

BioAtla's return on equity of -46.35% beat Compugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	N/A	-46.35%	-37.71%
BioAtla	N/A	-77.19%	-58.34%

Does the MarketBeat Community prefer CGEN or BCAB?

Compugen received 283 more outperform votes than BioAtla when rated by MarketBeat users. Likewise, 65.15% of users gave Compugen an outperform vote while only 62.07% of users gave BioAtla an outperform vote.

Company	Underperform	Outperform
Compugen	Outperform Votes 301 65.15%	Underperform Votes 161 34.85%
BioAtla	Outperform Votes 18 62.07%	Underperform Votes 11 37.93%

Which has more risk & volatility, CGEN or BCAB?

Compugen has a beta of 2.66, suggesting that its share price is 166% more volatile than the S&P 500. Comparatively, BioAtla has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Which has stronger valuation and earnings, CGEN or BCAB?

Compugen has higher revenue and earnings than BioAtla. Compugen is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$7.50M	10.63	-$33.69M	-$0.40	-2.30
BioAtla	$250K	288.71	-$106.48M	-$2.65	-0.57

Does the media favor CGEN or BCAB?

In the previous week, Compugen had 13 more articles in the media than BioAtla. MarketBeat recorded 13 mentions for Compugen and 0 mentions for BioAtla. Compugen's average media sentiment score of 0.94 beat BioAtla's score of 0.35 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Compugen	Neutral
BioAtla	Positive

Summary

Compugen beats BioAtla on 10 of the 17 factors compared between the two stocks.